About this raise
DeoBioSciences, with a post-money valuation of $16.67 million, is raising funds on NetCapital. The company is developing treatment against metastatic cancer in pets and people. The cancer drug will be based on a naturally-occurring compound that can kill both early and advanced-stage cancer cells. John F. Adamson founded DeoBioSciences in 2000. The proceeds of the current crowdfunding campaign, with a minimum raise of $10,000 and a maximum raise of $1,070,000, will be used for pre-clinical drug manufacturing, pre-clinical animal trials, payroll and benefits, R&D consultants, and other miscellaneous expenses. DeoBioSciences has received letters of interest from major biotech companies for in-licensing and partnerships.
Investment Overview
Invested : $110,350
Deal Terms
Total Commitments ($USD)
- Platform
- Netcapital
- Start Date
- 05/13/2021
- Close Date
- 03/15/2022
$10,000
$1,070,000
$100
Equity - Common
Pre-Seed
RegCF
$50.00
$15,600,000
Company & Team
Company
- Year Founded
- 2000
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B/B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.